solid get lost cloud concern
solid result strong underli growth concern asset
sale overdon view pleas jnj fundament
execut driven strong growth pharma stabl perform
devic consum said stock held back
concern manag fairli routin divestitur asp busi
decis maintain ep guidanc top-lin beat potenti
face headwind form lower asset sale
concern on-going litig relat talc opioid find
portfolio manag asset sale
reinvest effect note deliv solid
sharehold return past period slow asset sale
result reiter outperform rate target
on-going uncertainti relat litig remain continu view
stock attract current level
pharma ex-zytiga ex-darzalex adj immunolog
oncolog ph key driver growth
launch like erleada spravato still remain earli stage
devic consum remain stabl
organ afib stroke combin advanc surgeri
remain key driver md off-set ortho spine babi
beauti drove growth consum
valuat target price unchang base ebitda
multipl unchang estim ntm ebitda month forward
bil previous bil risk unexpect challeng pharma product
advers impact litig regulatori qualiti issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
pharmaceut bil mil y/i cc oper vs
immunolog sale driven stelara tremfya simponi aria partial
off-set remicad
oncolog sale driven darzalex one-tim benefit off-set lower
pulmonari hypertens sale driven sale opsumit uptravi
medic devic bil mil y/i cc oper
intervent solut sale oper driven continu dd
orthopaed oper driven hip sale trauma
off-set knee spine
surgeri sale strength advanc surgeri off-set
gener surgeri specialti surgeri
vision sale oper driven contact lenses/oth
off-set surgic
consum bil mil y/i cc oper vs cse
babi sale driven primarili last year comp relat
johnson relaunch partial off-set declin aveeno babi due
beauti sale driven dr ci labo acquisit along
share gain neutrogena aveeno
estimate
addit detail takeaway
pharmaceut bil mil y/i cc
immunolog sale bil mil oper growth
quarter driven strong uptak stelara crohn diseas primarili
crohn diseas indic strong launch uptak tremfya patient
therapi market share psoriasi market expand indic
simponi aria well overal immunolog market growth remicad sale
declin due increas discounts/reb biosimilar competit
infecti diseas sale mil mil oper
strong sale symtuza launch juluca hiv partial off-set
increas competit prezista/prezcobix/rezolsta prezista ou loe loss
neurosci sale bil mil oper
paliperidon long-act inject grew due strength invega trinza/trevicta
invega sustenna/xeplion partial off-set cannib risperd consta
lower sale concerta due gener competit compani continu
expand number certifi risk evalu mitig strategi rem center
support launch spravato reach
oncolog sale bil mil oper darzalex
continu strong market growth share gain eu driven patient
uptak line therapi well strong growth japan latin america sale
includ one-tim adjust relat complet price reimburs
discuss certain european countri posit impact ww oper
growth point mil darzalex sale grew benefit
strong market growth well market share gain across line therapi sale
imbruvica increas due on-going patient uptak ww higher market share well
increas penetr share gain emea well latin america
aspac compani also file regulatori submiss subcutan formul
darzalex multipl myeloma last week lower sale zytiga
result gener competit partial off-set strong sale share growth
ou erleada growth driven launch uptak along share gain non-
pulmonari hypertens sale mil mil oper
growth quarter driven strong sale opsumit uptravi result
continu market growth share gain sale tracleer lower due increas
use opsumit gener eu
cardiovascular/metabolism/oth sale bil mil
oper sale xarelto lower driven higher medicar part
util rebat higher donut hole util legisl
rebat chang partial off-set higher market share invokana/invokamet sale
lower due share loss competit pressur safeti label updat
estimate
medic devic bil mil y/i cc
intervent solut sale mil mil oper
electrophysiolog grew driven continu dd afib procedur growth along
strong thermocool smarttouch sf contact sens cathet diagnost
orthopaed sale bil mil oper hip
sale mil mil oper growth driven jnj
leadership posit anterior approach strong market demand acti stem
adopt kincis enabl hip procedur knee sale mil
mil oper manag cite competit pressur
 partial off-set continu uptak attun revis knee system strong
ou growth new product trauma sale mil mil
oper driven strong market growth continu uptak new product
spine sale mil mil oper
spine ww ou partial off-set growth sport
led monovisc growth dd growth aspac ortho price
pressur stabl compar pure price neg across categori
spine pure price declin hip knee trauma
surgeri sale bil mil oper advanc
surgeri sale bil mil oper endocutt
driven growth region due continu success new product
led ou growth mainli aspac due market growth share
gain new product along growth emea biosurgeri due
isol suppli disrupt gener surgeri sale bil mil
oper primarili due temporari stapler recal partial off-set wound
closur growth driven strong aspac perform relat market
share growth china well share gain convent barb sutur
specialti surgeri sale mil mil oper
due asp divestitur neg impact partial off-set mentor growth
vision sale bil mil oper contact
lenses/oth sale mil mil oper
growth led daili dispos astigmat lens oasi famili surgic
sale mil mil oper led declin
 partial off-set strength ou cataract result market perform
iol dd aspac growth
estimate
consum bil mil y/i cc
babi sale mil mil oper growth
quarter driven primarili last year comp relat johnson
relaunch partial off-set declin aveeno babi due channel shift
beauti sale bil mil oper growth
driven dr ci labo acquisit along share gain neutrogena aveeno
geograph channel expans ogx maui moistur vogu intern
partial off-set roc nizor divestitur
oral sale mil mil oper growth
driven new product launch favor prior year comparison
over-the-counter sale bil mil oper growth
driven zyrtec market share gain sale share growth pediatr analges
motrin tylenol continu strong consumpt growth tylenol partial off-set
retail stock dynam
women sale mil mil oper
declin quarter result competit pressur emea aspac
wound care/oth sale mil mil oper
due divestitur compe hra pharma
estimate
 oper margin bp estim
bottom line sale net cog lower sg higher
non-op incom net interest partial off-set higher tax share
deliv ep upsid rel estim consensu higher cog
result product mix off-set improv sg leverag pharmaceut
consum busi higher expect due higher invest
medic devic busi support develop digit surgeri platform
includ robot higher non-op incom primarili driven bil pre-tax
gain asp divestitur higher expect effect tax rate also
includ tax impact gain asp divestitur
manag rais sale growth guidanc adj op
growth bil ep guidanc remain unchang
sale
sale
estimate
ep
sale
sale
sale
chang model
increas sale estim leav ep estim
unchang also made rel minor adjust top-lin project
beyond trim sale estim per year averag leav
year ep estim unchang
figur chang model
target price unchang base ebitda multipl unchang
estim ntm ebitda month forward bil previous bil risk
unexpect challeng pharma product pipelin setback macro challeng around
drug price unexpect advers impact litig regulatori qualiti issu
charl martineau pm univers toronto compani mention price
